RecruitingPhase 3NCT05534672
Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex
Studying Tuberous Sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Katarzyna Kotulska
- Intervention
- Rapamycin(other)
- Enrollment
- 200 enrolled
- Eligibility
- 50 years · All sexes
- Timeline
- 2023 – 2027
Study locations (2)
- Medical University of Lodz, Lodz, Poland
- Children's Memorial Health Institute, Neurology and Epileptology, Warsaw, Poland
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05534672 on ClinicalTrials.govOther trials for Tuberous Sclerosis
Additional recruiting or active studies for the same condition.